Jorge L. Ramón

Medical Oncologist

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC review: iRECIST and atypical patterns of response to immuno-oncology drugs https://t.co/GD1hQe9p5o @j_lramon @SallyCMLau

[soria @jsoriamd]

10 years of cancer cellular immunotherapy, key challenges facing the field & strategies that are emerging to overcome these obstacles
https://t.co/HeZucN7QGa

[soria @jsoriamd]

Pre-treatment serum Albumin & TMB as predictors of #immunotherapy efficacy in #cancer
https://t.co/pgqMaAbxii

[Ravi A Madan M.D. @Dr_RaviMadan]

Bad cancer vs #immune mediated?

“#Nivolumab +/- #ipilimumab was NOT associated with an ⬆️ rate of progression vs placebo in pts… suggesting that previous reports of #hyperprogression may reflect the natural disease course… rather than ICI-mediated progression”

#immunotherapy

[Jorge L. Ramón @j_lramon]

@aredondo12 @MendiolaMarta Una recompensa que compartimos todos y demuestra que el trabajo en equipo es la mejor manera de alcanzar metas.

[Andrés Redondo @aredondo12]

Gracias @MendiolaMarta y @j_lramon por vuestro enorme esfuerzo, que por fin tiene su recompensa.
Espero que este trabajo pueda contribuir a una mejor clasificación del riesgo de las pacientes con cáncer de endometrio y, por tanto, a un tratamiento complementario más adecuado

[MSKCC Team Uterus @TeamEndo_MSK]

🎊Start off 2022 with this essential & comprehensive review of #EndometrialCancer in @Nature @DiseasePrimers!

Awesome collaboration by Dr. Vicky Makker, @DrHelenMacKay @CoquardRay @levinemd @ShannonWestin Dr. Aoki & @AnaOaknin
🇺🇸🇨🇦🇫🇷🇯🇵🇪🇸 #gyncsm

https://t.co/sGjgJCoEqM

[NatureRevClinOncol @NatRevClinOncol]

Hope you are enjoying our article countdown! The 6th most popular long article published in @NatRevClinOncol in 2021 discusses the role of the MYC oncogene in cancer https://t.co/iSiVXDAZ7o

[Andrés Redondo @aredondo12]

Acabamos de publicar en una prestigiosa revista uno de los proyectos de investigación de los q más orgulloso me siento, realizado en nuestro la laboratorio de Oncología Traslacional. Gracias @MendiolaMarta por tu tesón y entusiasmo sin los q este proyecto no habría sido posible

[The Oncologist @OncJournal]

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer

#Alpelisib #EndocrineTherapy #AdvancedBreastCancer #BreastCancer #PIK3CA

https://t.co/gvljgNWKZ0

[soria @jsoriamd]

Understanding the blood-tumor barrier is key to develop optimal new therapeutic approaches in #cancer. This review provides current knowledge of BTB structure & function with a focus on how this knowledge can be translated into clinical advances
https://t.co/LjxB3U4Zkr

[The Oncologist @OncJournal]

Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer

#Afatinib #Selumetinib #KRAS #ColorectalCancer #NonSmallCellLungCancer #PancreaticCancer
https://t.co/pkN68o8PWP

[Pedro T Ramirez @pedroramirezMD]

Completely agree! @IJGCfellows @IJGConline @ESGO_society @IGCSociety

[soria @jsoriamd]

Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options
https://t.co/Lt24YRXQWd

[Andres Cervantes @AndresC27622123]

Look at this critical review article by @LizzySmyth1 @ValeGambardella and @tfleitask in @Annals_Oncology on Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterog... https://t.co/jBWbEvD5QJ

[Ibrahim Halil SAHIN, MD @IbrahimSahinMD1]

A systemic review of TNT approach in rectal cancer https://t.co/gUiebeB9J9 showing improved pCR. The practice has already shifted to TNT approach to better delivery of planned therapy as well as to better understand the biology while data on survival outcomes maturing @OncoAlert

[Pedro T Ramirez @pedroramirezMD]

Just out today!! @IJGConline Really encourage all to take a look!...A great value for practicing #oncologists, #fellows, #residents, and anyone studying for their exams @IJGCfellows @IGCSociety @ESGO_society @GynMe4 #endometrial #cancer @ESTRO_RT

[Dimitrios Nasioudis @DNasioudis]

In our recent analysis, we found a rapid adoption of SLNBx in the U.S for patients with high-risk endometrial histologies. No difference in LN+ rate or overall survival between SLNBx and LND groups. https://t.co/Fw0ZFg0O51

[Joe Biden @JoeBiden]

It’s not enough to praise our essential workers — we have to protect and pay them.